ISOLATED HORIZONTAL SUPRANUCLEAR GAZE PALSY AS A MARKER OF SEVERE SYSTEMIC INVOLVEMENT IN GAUCHERS-DISEASE

被引:98
作者
PATTERSON, MC
HOROWITZ, M
ABEL, RB
CURRIE, JN
YU, KT
KANESKI, C
HIGGINS, JJ
ONEILL, RR
FEDIO, P
PIKUS, A
BRADY, RO
BARTON, NW
机构
[1] NINCDS, DMNB, BLDG 10, ROOM 3D03, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA
[2] NIDOCD, AUDIOL SECT, BETHESDA, MD USA
[3] MENTAL HLTH RES INST, MELBOURNE, AUSTRALIA
[4] NINCDS, MED NEUROL BRANCH, BETHESDA, MD 20892 USA
[5] NINCDS, BIOMETRY & FIELD STUDIES BRANCH, BETHESDA, MD 20892 USA
[6] TEL AVIV UNIV, IL-69978 TEL AVIV, ISRAEL
关键词
D O I
10.1212/WNL.43.10.1993
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Type 3 neuronopathic Gaucher's disease (GD3) is phenotypically heterogeneous. In many GD3 patients, progressive myoclonus and dementia dominate the illness, with death secondary to progressive CNS disease. We have designated this group as GD3a. We studied 14 children with Gaucher's disease, isolated horizontal supranuclear gaze palsy, and aggressive systemic disease, and designated this group as GD3b. In comparison with 13 children with type 1 non-neuronopathic Gaucher's disease, the GD3b children presented earlier, and were shorter, underweight, and more prone to cardiopulmonary, hepatic, and skeletal complications. One-half of the children died in childhood or adolescence of systemic complications. Patients with at least one copy of the mutation that causes substitution of asparagine for serine at amino acid 370 of glucocerebrosidase did not develop neurologic signs. Patients homoallelic for the mutation causing substitution of leucine for proline at position 444 had severe systemic disease; neurologic signs were frequently, but not invariably, present. Early diagnosis and timely enzyme replacement therapy promise to improve the prognosis in GD3b.
引用
收藏
页码:1993 / 1997
页数:5
相关论文
共 27 条
[1]  
AGRESTI A, 1990, CATEGORICAL DATA ANA, P17
[2]   REPLACEMENT THERAPY FOR INHERITED ENZYME DEFICIENCY - MACROPHAGE-TARGETED GLUCOCEREBROSIDASE FOR GAUCHERS-DISEASE [J].
BARTON, NW ;
BRADY, RO ;
DAMBROSIA, JM ;
DIBISCEGLIE, AM ;
DOPPELT, SH ;
HILL, SC ;
MANKIN, HJ ;
MURRAY, GJ ;
PARKER, RI ;
ARGOFF, CE ;
GREWAL, RP ;
YU, KT .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (21) :1464-1470
[3]   GAUCHER DISEASE - NEW MOLECULAR APPROACHES TO DIAGNOSIS AND TREATMENT [J].
BEUTLER, E .
SCIENCE, 1992, 256 (5058) :794-799
[4]   METABOLISM OF GLUCOCEREBROSIDES .2. EVIDENCE OF AN ENZYMATIC DEFICIENCY IN GAUCHERS DISEASE [J].
BRADY, RO ;
KANFER, JN ;
SHAPIRO, D .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1965, 18 (02) :221-&
[5]  
COGAN DG, 1981, ARCH OPHTHALMOL-CHIC, V99, P1802
[6]   NEUROPATHOLOGY OF THE NORRBOTTNIAN TYPE OF GAUCHER DISEASE - MORPHOLOGICAL AND BIOCHEMICAL-STUDIES [J].
CONRADI, NG ;
SOURANDER, P ;
NILSSON, O ;
SVENNERHOLM, L ;
ERIKSON, A .
ACTA NEUROPATHOLOGICA, 1984, 65 (02) :99-109
[7]  
ERIKSON A, 1986, ACTA PAEDIATR SCAND, P1
[8]  
FIRON N, 1990, AM J HUM GENET, V46, P527
[9]  
FRIEDE RL, 1989, DEV NEUROPATHOLOGY, P437
[10]   A CASE OF NONNEUROLOGIC GAUCHERS-DISEASE THAT BIOCHEMICALLY RESEMBLES THE NEUROLOGIC TYPES [J].
GLEW, RH ;
GOPALAN, V ;
HUBBELL, CA ;
BEUTLER, E ;
GEIL, JD ;
LEE, RE .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1991, 50 (02) :108-117